Braidwell’s Blueprint Medicines BPMC Stock Holding History

Braidwell’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-439,968	Closed	-$38.9M	–	58
2025 Q1	$38.9M	Buy	+439,968	New	+$42.9M	1.37%	31

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Braidwell's BPMC Position: Q2 2025 in Review

Braidwell sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 439,968 shares — an estimated $38.9M sold.

Braidwell first reported a position in BPMC in Q1 2025 and held it in 1 quarter. The position peaked at $38.9M in Q1 2025. 355 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Braidwell reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Braidwell sold 439,968 Blueprint Medicines shares in Q2 2025, an estimated $38.9M.
Braidwell first reported a position in Blueprint Medicines in Q1 2025 and held it in 1 quarter.
Braidwell's Blueprint Medicines position peaked at $38.9M in Q1 2025.
355 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.